Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 26531-26540 Newer>

The Motley Fool October 9, 2007 Morgan Housel	Meg Whitman's Tough Lessons What investing lessons can you learn from eBay's costly purchase of Skype?
The Motley Fool October 8, 2007 Mac Greer	Fool Video: A Breakup for Yahoo!? Gone are the days when Yahoo! could produce Google-sized or Baidu-sized returns for shareholders. Is it time for Yahoo! to launch a spinoff?
The Motley Fool October 8, 2007 Billy Fisher	Vital Signs at Medtronic The FDA raises question about Medtronic's Endeavor stent. Investors, remember that the company also has a well-diversified product portfolio to protect itself against any unforeseen pitfalls ahead.
The Motley Fool October 8, 2007 Brian Lawler	Noven's Acquisition Blues A recently acquired drug fails a late-stage clinical trial. Investors, take note.
The Motley Fool October 8, 2007 Matt Koppenheffer	The Kids Aren't All Right, Stan Investors, did the losses at Merrill really come out of the blue? An estimated total $20 billion of losses suggests that "limited" was a severe understatement.
The Motley Fool October 8, 2007 Toby Shute	Drilling Into Tesco This oilfield services company has some nifty gadgets, but plenty of fleas for investors.
The Motley Fool October 8, 2007 Anders Bylund	3 Stocks That Missed the Mark These three companies overpromised and underdelivered in their quarterly reports. Is it a signal to sell them, or are they turnaround candidates: Walgreen... RPM International... SMART Modular Technologies...
The Motley Fool October 8, 2007 Alyce Lomax	A Big Bid for E-Bookworms Sony and Borders are hoping for a blockbuster hit in digital books. Investors will have to wait a few quarters to see how it turns out for these companies.
The Motley Fool October 8, 2007 Billy Fisher	McKesson Expands Its Empire A new acquisition strengthens the company's presence in the cancer drug market. Investors, take note.
The Motley Fool October 8, 2007 Billy Fisher	A Menace to Big Pharma Abraxis gets tentative approval for a generic version of Pfizer's Camptosar. Many of the large-cap pharmaceutical companies are diversified to such a degree that they, like Abraxis, present interesting plays on the threat posed by generics.
<Older 26531-26540 Newer> Return to current articles.